A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight increase in new diabetic retinopathy cases but fewer severe eye complications, ...

Empowering choice in the pharmacological management of type 2 diabetes One in nine people worldwide lives with diabetes, with 90% affected by type 2 diabetes.1 Despite ongoing advances in therapy and ...

Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second ...

More evidence shows a risk between GLP-1 drugs and vision risks. A study in JAMA Network Open adds more evidence linking ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION).

Aging brings wisdom, experience, and often, a host of changes — including those that affect our vision. "By the time most people reach their forties, the eye begins to undergo physiological ...

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition that can lead to sudden vision loss due to lack of blood flow.